Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.

Boon H, Bosselaar M, Praet SF, Blaak EE, Saris WH, Wagenmakers AJ, McGee SL, Tack CJ, Smits P, Hargreaves M, van Loon LJ

Diabetologia16 Aug 2008Cited by 92 (Europe PMC)

PMID18709353DOI10.1007/s00125-008-1108-7PepBankPUB-18709353

Source link PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR reduced plasma glucose appearance rate compared with control.
In plain wordsIn men with diabetes, AICAR reduced glucose appearance compared with control.
Peptide
AICAR (acadesine)
Outcome
DecreaseGlucose appearance rate
Study
n = 10
Comparator
NaCl control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Plasma glucose rate of appearance (R (a)) was reduced following AICAR administration, while plasma glucose rate of disappearance (R (d)) was similar in the AICAR and control test.
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935301
02HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, plasma glucose disappearance rate was similar with AICAR and control.
In plain wordsIn men with diabetes, glucose disappearance was similar with AICAR and control.
Peptide
AICAR (acadesine)
Outcome
No significant changeGlucose disappearance rate
Study
n = 10
Comparator
NaCl control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Plasma glucose rate of appearance (R (a)) was reduced following AICAR administration, while plasma glucose rate of disappearance (R (d)) was similar in the AICAR and control test.
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935302
03HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR increased glucose disposal expressed relative to glucose appearance.
In plain wordsIn men with diabetes, AICAR increased relative glucose disposal compared with control.
Peptide
AICAR (acadesine)
Outcome
IncreaseRelative glucose disposal
Study
n = 10
Comparator
NaCl control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Consequently, blood glucose disposal (R (d) expressed as a percentage of R (a)) was increased following AICAR infusion (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935303
04HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR produced a greater decline in plasma glucose concentration than control.
In plain wordsIn men with diabetes, AICAR lowered blood glucose more than control.
Peptide
AICAR (acadesine)
Outcome
DecreasePlasma glucose concentration
Study
n = 10
Comparator
NaCl control
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Accordingly, a greater decline in plasma glucose concentration was observed following AICAR infusion (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935304
05HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR significantly reduced plasma NEFA appearance rate.
In plain wordsIn men with diabetes, AICAR reduced fatty acid appearance compared with control.
Peptide
AICAR (acadesine)
Outcome
DecreaseNEFA appearance rate
Study
n = 10
Comparator
NaCl control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Plasma NEFA R (a) and R (d) were both significantly reduced in response to AICAR infusion, and were accompanied by a significant decline in plasma NEFA concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935305
06HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR significantly reduced plasma NEFA disappearance rate.
In plain wordsIn men with diabetes, AICAR reduced fatty acid disappearance compared with control.
Peptide
AICAR (acadesine)
Outcome
DecreaseNEFA disappearance rate
Study
n = 10
Comparator
NaCl control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Plasma NEFA R (a) and R (d) were both significantly reduced in response to AICAR infusion, and were accompanied by a significant decline in plasma NEFA concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935306
07HumanNon-randomized trialEfficacy outcome
In men with type 2 diabetes, AICAR significantly reduced plasma NEFA concentration.
In plain wordsIn men with diabetes, AICAR lowered blood fatty acids compared with control.
Peptide
AICAR (acadesine)
Outcome
DecreasePlasma NEFA concentration
Study
n = 10
Comparator
NaCl control
Outcome group
Lipids · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Plasma NEFA R (a) and R (d) were both significantly reduced in response to AICAR infusion, and were accompanied by a significant decline in plasma NEFA concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935307
08HumanNon-randomized trialMechanism
In men with type 2 diabetes, AICAR did not increase skeletal muscle AMPK phosphorylation.
In plain wordsIn men with diabetes, AICAR did not increase muscle AMPK phosphorylation compared with control.
Peptide
AICAR (acadesine)
Outcome
No significant changeMuscle AMPK phosphorylation
Study
n = 10
Comparator
NaCl control
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Source sentences
Summary
Although AMPK phosphorylation in skeletal muscle was not increased, we observed a significant increase in acetyl-CoA carboxylase phosphorylation (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935308
09HumanNon-randomized trialMechanism
In men with type 2 diabetes, AICAR significantly increased acetyl-CoA carboxylase phosphorylation.
In plain wordsIn men with diabetes, AICAR increased ACC phosphorylation compared with control.
Peptide
AICAR (acadesine)
Outcome
IncreaseMuscle ACC phosphorylation
Study
n = 10
Comparator
NaCl control
Outcome group
Receptor activity and mechanism · Metabolic and weight
Studied dose
0.75 mg kg(-1) min(-1) · intravenousAs given in this study (human).
Measurements
P value
< 0.001 NA
muscle ACC phosphorylation
Source sentences
Summary
Although AMPK phosphorylation in skeletal muscle was not increased, we observed a significant increase in acetyl-CoA carboxylase phosphorylation (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg(-1) min(-1)) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 +/- 2 years; BMI 28 +/- 1 kg/m(2)).
Report a problemFND-1870935309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.